BrightHeart View Classifier vs Imbio PHA (4.0.0)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by BrightHeart
VS
by Imbio (a subsidiary of 4DMedical)

AI Verdict

Tool A specializes in AI-powered guidance and analysis for prenatal ultrasound exams, focusing on congenital heart defect detection and exam completeness. Conversely, Tool B uses AI to measure cardiac structures from CT pulmonary angiogram scans to assess right ventricular dilation for pulmonary embolism and hypertension. While both are FDA-cleared cardiology AI tools, their distinct imaging modalities and clinical applications make them suitable for different stages of patient care and different medical specialties.

Choose BrightHeart View Classifier if…

Choose BrightHeart View Classifier if your primary need is real-time, AI-powered guidance during prenatal ultrasound exams to enhance the detection of congenital heart defects and ensure comprehensive fetal heart screening. This tool is ideal for obstetrics and maternal-fetal medicine practices aiming to improve exam completeness and consistency, regardless of operator experience.

View BrightHeart View Classifier →

Choose Imbio PHA (4.0.0) if…

Choose Imbio PHA (4.0.0) if you require automated, AI-driven analysis of cardiac structures from CT pulmonary angiogram (CTPA) scans to assess right ventricular dilation. This solution is best suited for radiology, cardiology, and pulmonology departments focused on aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension through rapid, post-acquisition image processing.

View Imbio PHA (4.0.0) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature BrightHeart View Classifier Imbio PHA (4.0.0)
Deployment Seamless integration into existing ultrasound workflows, plug and play solution, compatible with major ultrasound manufacturers and existing reporting solutions, automatic display on cart-side tablet during scan, results summarized and linked in reporting software, detailed assessments on standalone web platform. Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel).
FDA Status Yes AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

BrightHeart View Classifier

BrightHeart View Classifier (Tool A) offers real-time guidance during prenatal ultrasound exams via a cart-side tablet, providing immediate, interactive assistance to the sonographer during the procedure itself. This direct, in-workflow guidance enhances the user experience at the point of care. Imbio PHA (Tool B) focuses more on automated post-acquisition processing and reporting, which, while efficient, is less interactive during the actual image acquisition.

Clinical Value

BrightHeart View Classifier

BrightHeart View Classifier (Tool A) directly enhances the detection of congenital heart defects and ensures exam completeness during prenatal ultrasounds, a critical area with often missed diagnoses. It has published clinical evidence demonstrating an improvement in congenital heart defect detection rates to over 96% and a reduction in reading times by 18%. While Imbio PHA (Tool B) provides valuable automated measurements for pulmonary embolism and hypertension, Tool A's quantifiable impact on early, life-saving diagnosis gives it a slight edge.

Pricing & Value

Tie

Neither BrightHeart View Classifier (Tool A) nor Imbio PHA (Tool B) publicly discloses its pricing information. Both require contacting the vendor for custom pricing details, making a direct head-to-head comparison on this dimension impossible based on available information.

Enterprise Readiness

Imbio PHA (4.0.0)

Imbio PHA (Tool B) demonstrates stronger enterprise readiness by offering flexible deployment options, including cloud and on-premise, and explicitly stating HIPAA compliance with third-party certification and the availability of a Business Associate Agreement (BAA). BrightHeart View Classifier (Tool A) is cloud-based and mentions on-site pseudonymization but lacks explicit public statements regarding HIPAA compliance and BAA availability, which is crucial for enterprise adoption.

Innovation

BrightHeart View Classifier

BrightHeart View Classifier (Tool A) stands out with its real-time AI-powered guidance and feedback delivered via a cart-side tablet during the actual prenatal ultrasound acquisition. This proactive, in-workflow assistance for ensuring exam completeness and flagging potential congenital heart defects represents a more novel and disruptive application of AI compared to Imbio PHA's (Tool B) automated post-acquisition measurements from CT scans.

Support & Docs

Imbio PHA (4.0.0)

Imbio PHA (Tool B) provides comprehensive and transparent support channels, including phone, email, and an online case submission system with 24/7/365 monitoring for online inquiries. It also explicitly mentions the availability of user manuals and product documentation. In contrast, public information regarding specific support or documentation for BrightHeart View Classifier (Tool A) is not readily available.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature BrightHeart View Classifier Imbio PHA (4.0.0)
Name BrightHeart View Classifier Imbio PHA (4.0.0)
Company BrightHeart Imbio
Description BrightHeart's B-Right AI Platform, including the B-Right Views tool, provides AI-powered guidance and analysis for prenatal ultrasound exams, enhancing the detection of congenital heart defects and ensuring exam completeness. Imbio PHA (4.0.0) is an FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.
Primary Imaging Modality Prenatal Ultrasound CT Pulmonary Angiogram (CTPA)
Key Functionality AI-powered analysis of fetal heart ultrasound exams, real-time guidance, automatic detection of standard fetal heart views, flags potential structural abnormalities, ensures exam completeness. Automated measurement of cardiac structures (RV/LV, PA/Ao diameters and ratios), anatomical identification, generates annotated DICOM images and PDF reports.

Videos

Demos, reviews, and walkthroughs featuring BrightHeart View Classifier and Imbio PHA (4.0.0).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

BrightHeart View Classifier provides AI-powered guidance and analysis for prenatal ultrasound exams. Imbio PHA (4.0.0) automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans.
BrightHeart View Classifier enhances the detection of congenital heart defects and ensures exam completeness during prenatal ultrasound exams. Imbio PHA (4.0.0) assesses potential right ventricular dilation and aids in the diagnosis and risk stratification of pulmonary embolism and hypertension.
BrightHeart View Classifier provides real-time guidance during prenatal ultrasound exams via a cart-side tablet. Imbio PHA (4.0.0) offers rapid, fully-automated assessment, typically in minutes, which implies post-processing of CTPA scans.
BrightHeart View Classifier automatically detects and confirms standard fetal heart views and flags potential structural abnormalities suggestive of congenital heart defects. Imbio PHA (4.0.0) automatically measures right and left ventricle diameters, main pulmonary artery and aorta diameters, and calculates RV/LV and PA/Ao ratios from CTPA scans.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.